Acalabrutinib
- Generic Name
- Acalabrutinib
- Brand Names
- Calquence
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23N7O2
- CAS Number
- 1420477-60-6
- Unique Ingredient Identifier
- I42748ELQW
- Background
To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others.
...
- Indication
Acalabrutinib is currently indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy. It has also been recently approved for chronic lymphocytic leukemia and small lymphocytic lymphoma.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL), Small Lymphocytic Lymphoma
- Associated Therapies
- -
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 62
- Registration Number
- NCT04380688
- Locations
- 🇺🇸
Research Site, Renton, Washington, United States
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 177
- Registration Number
- NCT04346199
- Locations
- 🇹🇷
Research Site, Umraniye, Turkey
Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder
- Conditions
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Deepa Jagadeesh
- Target Recruit Count
- 6
- Registration Number
- NCT04337827
- Locations
- 🇺🇸
Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
- Conditions
- Primary Mediastinal (Thymic) Large B-Cell LymphomaB-Cell Non-Hodgkin LymphomaGrade 3a Follicular LymphomaTransformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular Lymphoma
- Interventions
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 50
- Registration Number
- NCT04257578
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease
- Conditions
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT04198922
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 2
- Registration Number
- NCT04189952
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT04189757
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Acalabrutinib and Venetoclax with or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 168
- Registration Number
- NCT04169737
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 360
- Registration Number
- NCT04115631
- Locations
- 🇺🇸
Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States
🇺🇸Providence Newberg Medical Center, Newberg, Oregon, United States
🇺🇸Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States
Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- First Posted Date
- 2019-09-18
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 66
- Registration Number
- NCT04094142
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.